Plain-English translation of NCT06570447 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether combining two medications— and —can help treat aggressive lymphoma (a blood cancer) that has come back or stopped responding to previous treatments. You would receive this medication combination over several treatment cycles. Researchers want to see if this new approach is safe and effective for patients like you.
Many people with aggressive lymphoma find that standard treatments stop working after a while, leaving them with limited options. This medication combination is being studied to see if it offers hope for patients whose cancer has become resistant to other therapies.
You likely qualify if…
You likely don't qualify if…
You would need to stay in the hospital for observation after receiving your first doses of the medication, as this is a requirement of the study. Then you would receive the medication combination in repeating 3-week cycles for up to 12 cycles (about 9 months). During this time, you would have regular visits for blood tests, imaging scans, and check-ins with the study team to monitor how you're responding and manage any side effects.
AI-generated summary from trial data · Oct 22, 2026 · Not medical advice
China